BTK Inhibitor-Containing Bridging Therapy and CAR-T Outcomes in R/R LBCL
Association of Disease Control After BTK Inhibitor-Containing Bridging Therapy and Systemic Inflammatory Phenotypes With CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma
This observational study will examine outcomes of CAR-T cell therapy in adults with large B-cell lymphoma that has returned or has not responded to prior treatment. Participants will already have received bridging therapy that includes a BTK inhibitor before CAR-T cell infusion.
Researchers will compare outcomes between participants whose lymphoma responded to bridging therapy before CAR-T cell infusion and those whose lymphoma did not respond. The study will use medical records, imaging results, laboratory tests, treatment information, and follow-up data collected during usual care. It will not assign treatment, change medical care, or require extra tests or blood samples.
The study will assess lymphoma response after CAR-T cell therapy, safety, survival, and changes in routine blood markers of inflammation after CAR-T cell therapy.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The study population comprises adults with relapsed or refractory large B-cell lymphoma (LBCL) who receive routine CAR-T cell therapy at a single center in China. Eligible patients receive BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy and have evaluable disease status after bridging therapy and before CAR-T cell infusion. Patients treated before ethics approval will be identified retrospectively from the center's CAR-T treatment records and routine medical records; eligible patients treated after ethics approval will be enrolled prospectively using the same criteria.
Beschreibung
Inclusion Criteria:
- Age ≥18 year.
- Relapsed or refractory large B-cell lymphoma (LBCL) after one or more prior lines of systemic therapy, including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS); diffuse large B-cell lymphoma transformed from follicular lymphoma (tFL); grade 3B follicular lymphoma (FL3B); primary mediastinal large B-cell lymphoma (PMBCL); and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit/triple-hit lymphoma, DHL/THL).
- Completion of CAR-T cell infusion at this center.
- Receipt of BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy.
- Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.
- Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.
Exclusion Criteria:
- Inability to verify the specific BTK inhibitor(s) used, treatment start and stop dates, or information on combination therapy, thereby precluding confirmation of exposure to BTK inhibitorcontaining bridging therapy.
- Absence of disease assessment data between bridging therapy and CAR-T cell infusion, with post-bridging disease status not determinable from imaging reports or medical records.
- Major discrepancies in key baseline or treatment data that persist after review of medical records, imaging, and treatment documentation, precluding determination of bridging exposure or group assignment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: OTHER
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Bridging Response (CR/PR)
Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort achieved complete response (CR) or partial response (PR). Treatments were determined as part of usual clinical care and were not assigned by the study. |
Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study. CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study. |
|
No Bridging Response (SD/PD)
Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort had stable disease (SD) or progressive disease (PD). Treatments were determined as part of usual clinical care and were not assigned by the study. |
Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study. CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Best objective response rate after CAR-T cell infusion
Zeitfenster: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
The proportion of participants who achieve complete response (CR) or partial response (PR) at any time after CAR-T infusion and before first progression, death, initiation of new anti-lymphoma therapy, or last evaluable disease assessment. Participants without CR/PR before these events are classified as nonresponders; progression or death after CR/PR does not change responder status. |
At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Duration of response
Zeitfenster: From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.
|
Among participants who achieve CR or PR, duration of response is measured from the date of first documented CR or PR to disease progression or death from any cause, whichever occurs first. Participants without progression or death will be censored at the last evaluable disease assessment or before initiation of subsequent anti-lymphoma therapy. |
From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.
|
|
Complete response rate at 1 month after CAR-T cell infusion
Zeitfenster: Approximately 1 month after CAR-T cell infusion.
|
Approximately 1 month after CAR-T cell infusion.
|
|
|
Best complete response rate after CAR-T cell infusion
Zeitfenster: At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
|
|
|
Number of participants with CAR-T treatment-emergent adverse events
Zeitfenster: From CAR-T cell infusion to last follow-up.
|
The number and percentage of participants with any adverse event occurring after CAR-T cell infusion will be reported. Safety events include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, prolonged cytopenia, death, and other clinically documented adverse events considered related to CAR-T cell therapy. CRS and ICANS will be graded according to ASTCT consensus criteria; other events will be collected from routine clinical, laboratory, and medical-record data. |
From CAR-T cell infusion to last follow-up.
|
|
Objective response rate at 1 month after CAR-T cell infusion
Zeitfenster: Approximately 1 month after CAR-T cell infusion.
|
Approximately 1 month after CAR-T cell infusion.
|
|
|
Objective response rate at 3 month after CAR-T cell infusion
Zeitfenster: Approximately 3 months after CAR-T cell infusion.
|
Approximately 3 months after CAR-T cell infusion.
|
|
|
Complete response rate at 3 months after CAR-T cell infusion
Zeitfenster: 3 months after CAR-T cell infusion
|
3 months after CAR-T cell infusion
|
|
|
Progression-free survival
Zeitfenster: From CAR-T infusion to first progression, death, or last follow-up.
|
From CAR-T infusion to first progression, death, or last follow-up.
|
|
|
Overall survival
Zeitfenster: From CAR-T infusion to death from any cause or last follow-up.
|
From CAR-T infusion to death from any cause or last follow-up.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- BTK-CART-2026
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .